Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. McDowell (Belfast, United Kingdom), S. Diver (Leicester, United Kingdom), J. Yang (Glasgow, United Kingdom), C. Borg (Oxford, United Kingdom), J. Busby (Belfast, United Kingdom), V. Brown (Belfast, United Kingdom), R. Shrimanker (Oxford, United Kingdom), C. Cox (Belfast, United Kingdom), C. Brightling (Leicester, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom), I. Pavord (Oxford, United Kingdom), L. Heaney (Belfast, United Kingdom). Late Breaking Abstract - Phenotyping Mepolizumab EXacerbations in severe eosinophilic asthma (MEX). 2250

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Use of mepolizumab in bronchiectasis with underlying eosinophilic condition Source: International Congress 2018 – New methods for diagnosing and treating lung diseases Year: 2018 Late Breaking Abstract - Characteristics of T2-biomarker low severe asthma patients in the UK Severe Asthma Registry (UKSAR) Source: International Congress 2019 – Asthma epidemiology in the 21st century Year: 2019 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract: Persistent effect of bronchial thermoplasty (BT) in severe asthma at two years Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED). Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Late Breaking Abstract - Airway hyperresponsiveness in bronchiectasis Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018